Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Business & Industry
- Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union
- Lilly and Amgen announce manufacturing collaboration for COVID-19 antibody therapies
- Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial
- COVID-19 vaccine AZD1222 clinical trials resumed in the UK
- CureVac expected to receive up to 252 million euros from the German Federal Ministry of Research for further COVID-19 vaccine development and production capacity expansion
Research & Development
- T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
- Designed antiviral proteins inhibit SARS-CoV-2 in the lab
- Progress toward antiviral treatments for COVID-19
- Tiny antibody component highly effective against SARS-COV-2 in animal studies
- Which immune response could cause a vaccine against COVID-19?
- Genome analyses track SARS-CoV-2's early introduction to the US and Europe
- COVID-19 study links strict social distancing to much lower chance of infection
Conferences & Events
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
- Preparing for the new world of drug safety: Embracing cloud and AI
- Pre-filled Syringes San Francisco Conference 2020
- Oligonucleotide Therapeutics and Delivery Conference 2020
Regulatory Affairs
- FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment
- FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines
- FDA announces first of its kind pilot program to communicate patient reported outcomes from cancer clinical trials
- FDA revokes emergency use authorization for chloroquine and hydroxychloroquine
- Global regulators commit to cooperate on observational research in the context of COVID-19